PYC Therapeutics

15 July 2026

RESULTS OF EXTRAORDINARY GENERAL MEETING

PERTH, Australia and SAN FRANCISCO, California – 15 July 2026

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, PYC Therapeutics Limited (the 'Company') provides the following information in relation to the resolutions contained in the Notice of Meeting dated 12 June 2026 and considered at today's Extraordinary General Meeting of Shareholders.

All resolutions were carried following a poll conducted at the meeting. The proxies received in respect of each resolution and the results of the poll are set out in the attached results summary.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development[1].

For more information, visit pyctx.com, or follow us on LinkedIn.

CONTACT US

Investor relations and media contact
investor@pyctx.com

[1] Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank https://doi.org/10.1101/2020.11.02.20222232

Summary of Results

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Approval of the PYC Therapeutics Limited Rights Plan	P	421,972,545	395,776,876 93.79%	26,172,616 6.20%	8,776	23,053 0.01%	395,799,929 93.80%	26,172,616 6.20%	8,776	Carried
2 Increase the constitutional cap on Non-Executive Director remuneration	P	421,626,786	398,309,640 94.47%	23,303,047 5.53%	26,535	14,099 0.00%	398,323,739 94.47%	23,303,047 5.53%	26,535	Carried
3 Approval to issue options to Dr. Rohan Hockings	P	421,543,059	366,541,132 86.95%	54,978,128 13.04%	438,262	23,799 0.01%	366,564,931 86.96%	54,978,128 13.04%	438,262	Carried